Acurx Pharmaceuticals Advances Novel Antibiotic Toward Phase 3 Trials

Jun 16, 2026

Acurx Pharmaceuticals (NASDAQ: ACXP) is advancing its lead antibiotic candidate, ibezapolstat (IBZ), toward international Phase 3 clinical trials for the treatment of Clostridioides difficile infection (CDI). The late-stage biopharmaceutical company is developing a new class of small-molecule antibiotics designed to combat difficult-to-treat bacterial infections, including multidrug-resistant gram-positive pathogens.

Recent research has provided new insights into the structural biology of DNA Pol IIIC, helping researchers better understand the mechanism of action and selectivity of ibezapolstat. According to the company, these findings support the continued development of its antibiotic platform while reinforcing its potential to preserve healthy gut microbiota and address a significant unmet medical need.

#AcurxPharmaceuticals
#ACXP
#Antibiotics
#Biotech
#ClinicalTrials
#Phase3
#CDiff
#CdiffInfection
#DrugDevelopment
#HealthcareInnovation
#MedicalResearch
#Pharmaceuticals
#NASDAQ
#JaneKing
#NewsOut